Eloxx Pharmaceuticals, Inc. SEC filings ELOX
Eloxx Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Dec 23, 2008. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Oct 22, 2026 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 22, 2026 | Oct 19, 2026 |
| 4 | Insider transaction | Oct 21, 2026 | Oct 19, 2026 |
| 3 | Initial insider ownership | Oct 21, 2026 | Oct 19, 2026 |
| EFFECT | Filing | Sep 18, 2026 | — |
| S-1 | Registration statement | Sep 11, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 27, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 17, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 17, 2026 | — |
| 4 | Insider transaction | Jun 17, 2026 | Jun 10, 2026 |
| 3 | Initial insider ownership | Jun 17, 2026 | Jun 5, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 16, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 16, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 15, 2026 | — |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 424B4 | Prospectus | Jun 9, 2026 | — |
| EFFECT | Filing | Jun 8, 2026 | — |
| CERT | Filing | Jun 8, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jun 5, 2026 | — |
| 4 | Insider transaction | Jun 5, 2026 | May 27, 2026 |
| S-1/A | Amended registration statement | Jun 4, 2026 | — |
| 8-A12B | Filing | Jun 1, 2026 | — |
| S-1/A | Amended registration statement | Jun 1, 2026 | — |
| 8-K |
Current report
Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Jun 1, 2026 | May 27, 2026 |
| 3 | Initial insider ownership | Jun 1, 2026 | May 27, 2026 |
| 3 | Initial insider ownership | Jun 1, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 29, 2026 | — |
| 4 | Insider transaction | May 8, 2026 | Sep 19, 2025 |
| 4 | Insider transaction | May 8, 2026 | Feb 6, 2022 |
| 4 | Insider transaction | May 8, 2026 | Sep 19, 2025 |
| DEF 14C | Information statement | May 8, 2026 | May 8, 2026 |
| S-1 | Registration statement | May 7, 2026 | — |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 3 | Initial insider ownership | May 4, 2026 | Apr 28, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 4, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 1, 2026 | — |
| 3 | Initial insider ownership | May 1, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 1, 2026 | Apr 28, 2026 |
| PRE 14C | Filing | Apr 28, 2026 | Apr 28, 2026 |
| DRS | Filing | Mar 20, 2026 | — |
| 10-K | Annual report | Mar 17, 2026 | Dec 31, 2025 |
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 12, 2025 | Aug 6, 2025 |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| SEC STAFF ACTION | Filing | Feb 21, 2025 | — |
| 4 | Insider transaction | Jan 28, 2025 | Jan 24, 2025 |
| 4 | Insider transaction | Jan 28, 2025 | Jan 24, 2025 |
| 4 | Insider transaction | Jan 28, 2025 | Jan 24, 2025 |
| 4 | Insider transaction | Jan 28, 2025 | Jan 24, 2025 |
| NT 10-Q | Filing | Nov 19, 2024 | Sep 30, 2024 |
| 4 | Insider transaction | Oct 17, 2024 | Oct 16, 2024 |
| 4 | Insider transaction | Oct 17, 2024 | Oct 16, 2024 |
| 4 | Insider transaction | Oct 17, 2024 | Oct 16, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 17, 2024 | Oct 16, 2024 |
| 4 | Insider transaction | Oct 17, 2024 | Oct 16, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Aug 20, 2024 | — |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 16, 2024 | Jul 10, 2024 |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| NT 10-K | Form nt 10-k | Apr 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 29, 2024 | Mar 25, 2024 |
| 25-NSE | Delisting notice | Mar 21, 2024 | — |
| 8-K |
Current report
Material agreement
|
Mar 14, 2024 | Mar 11, 2024 |
| 4 | Insider transaction | Jan 26, 2024 | Jan 24, 2024 |
| 4 | Insider transaction | Jan 26, 2024 | Jan 24, 2024 |
| 4 | Insider transaction | Jan 26, 2024 | Jan 24, 2024 |
| 4 | Insider transaction | Jan 26, 2024 | Jan 24, 2024 |
| S-3 | Shelf registration | Jan 25, 2024 | — |
| S-8 | Employee stock plan registration | Jan 24, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 9, 2024 | Jan 9, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 28, 2023 | Dec 27, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 15, 2023 | Dec 15, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Listing notice
|
Oct 16, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 20, 2023 | Sep 18, 2023 |
| 424B5 | Prospectus supplement | Sep 20, 2023 | — |
| 8-K |
Current report
Other events
|
Sep 18, 2023 | Sep 18, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 15, 2023 | Sep 15, 2023 |
| 8-K |
Current report
Other events
|
Sep 7, 2023 | Sep 7, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 29, 2023 | Aug 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 21, 2023 | Aug 21, 2023 |
| 8-K |
Current report
Acquisition or sale of assets
|
Aug 14, 2023 | Aug 14, 2023 |
| 424B5 | Prospectus supplement | Aug 11, 2023 | — |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Other events
|
Aug 3, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Other events
|
Jul 13, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Other events
|
Jun 15, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Other events
|
Jun 7, 2023 | Jun 6, 2023 |
| 424B5 | Prospectus supplement | May 24, 2023 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Other events
|
May 24, 2023 | May 24, 2023 |
| 8-K |
Current report
Results of operations
|
May 16, 2023 | May 15, 2023 |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 22, 2023 |
| CT ORDER | Filing | Apr 24, 2023 | — |
| 8-K |
Current report
Listing notice
|
Apr 14, 2023 | Apr 11, 2023 |
| 8-K |
Current report
Results of operations
|
Apr 3, 2023 | Apr 3, 2023 |
| S-8 | Employee stock plan registration | Mar 31, 2023 | — |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 9, 2023 | Mar 7, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| 4 | Insider transaction | Jan 31, 2023 | Jan 30, 2023 |
| 4 | Insider transaction | Jan 31, 2023 | Jan 30, 2023 |
| 4 | Insider transaction | Jan 31, 2023 | Jan 30, 2023 |
| 4 | Insider transaction | Jan 31, 2023 | Jan 30, 2023 |
| 4 | Insider transaction | Jan 27, 2023 | Jan 25, 2023 |
| 4 | Insider transaction | Jan 27, 2023 | Jan 25, 2023 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Dec 1, 2022 | Nov 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2022 | Nov 10, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| DEF 14A | Proxy statement | Oct 31, 2022 | Nov 30, 2022 |
| PRE 14A | Preliminary proxy statement | Oct 17, 2022 | Nov 30, 2022 |
| 8-K |
Current report
Listing notice
|
Oct 14, 2022 | Oct 11, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 15, 2022 | Sep 14, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 15, 2022 | Aug 15, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Auditor change
|
Jul 15, 2022 | Jul 13, 2022 |
| 4 | Insider transaction | Jul 6, 2022 | Jul 1, 2022 |
| 3 | Initial insider ownership | Jul 6, 2022 | Jul 1, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 5, 2022 | Jun 28, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 424B5 | Prospectus supplement | May 6, 2022 | — |
| 10-Q | Quarterly report | May 6, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Results of operations
|
Apr 4, 2022 | Mar 31, 2022 |
| 10-K | Annual report | Mar 30, 2022 | Dec 31, 2021 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 3, 2022 | — |
| 8-K |
Current report
Listing notice
|
Jan 5, 2022 | Jan 3, 2022 |
| 4 | Insider transaction | Dec 3, 2021 | Dec 1, 2021 |
| 4 | Insider transaction | Dec 3, 2021 | Dec 1, 2021 |
| 4 | Insider transaction | Dec 3, 2021 | Dec 1, 2021 |
| 4 | Insider transaction | Dec 1, 2021 | Nov 29, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 17, 2021 | Nov 17, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 10-Q | Quarterly report | Nov 8, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt
|
Oct 5, 2021 | Sep 30, 2021 |
| 424B5 | Prospectus supplement | Sep 30, 2021 | — |
| 8-K |
Current report
Material agreement, Other events
|
Sep 30, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 13, 2021 | Sep 13, 2021 |
| EFFECT | Filing | Aug 30, 2021 | — |
| CORRESP | Letter to the SEC | Aug 26, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2021 | — |
| S-3 | Shelf registration | Aug 20, 2021 | — |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2021 | Aug 17, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2021 | Aug 16, 2021 |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 4 | Insider transaction | Jul 30, 2021 | Jul 30, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 16, 2021 | Jul 14, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Jul 6, 2021 | Jun 30, 2021 |
| SC 13G | Ownership over 5% (passive) | Jun 29, 2021 | — |
| 8-K/A | Amended current report | Jun 16, 2021 | Apr 1, 2021 |
| SC 13G | Ownership over 5% (passive) | Jun 14, 2021 | — |
| 8-K |
Current report
Other events
|
May 27, 2021 | May 27, 2021 |
| 4 | Insider transaction | May 26, 2021 | May 25, 2021 |
| SC 13D/A | Amended ownership over 5% (active) | May 21, 2021 | — |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 19, 2021 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2021 | May 19, 2021 |
| 4 | Insider transaction | May 18, 2021 | May 18, 2021 |
| 4 | Insider transaction | May 18, 2021 | May 18, 2021 |
| 8-K |
Current report
Other events
|
May 18, 2021 | May 18, 2021 |
| 8-K |
Current report
Material agreement
|
May 18, 2021 | May 13, 2021 |
| 424B5 | Prospectus supplement | May 17, 2021 | — |
| 4 | Insider transaction | May 17, 2021 | May 13, 2021 |
| 4 | Insider transaction | May 17, 2021 | May 13, 2021 |
| 4 | Insider transaction | May 17, 2021 | May 13, 2021 |
| 4 | Insider transaction | May 17, 2021 | May 13, 2021 |
| 424B5 | Prospectus supplement | May 13, 2021 | — |
| 10-Q | Quarterly report | May 7, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 7, 2021 | May 6, 2021 |
| 4 | Insider transaction | May 3, 2021 | Apr 30, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELOX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1035354
- Former names
- Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.